ALLEGAN – Perrigo Tuesday announced that it has acquired the exclusive U.S. store brand rights to sell and distribute OTC versions of Fexofenadine HCl 180 mg and 60 mg tabs, plus Fexofenadine HCl 60 mg and Pseudoephedrine 120 mg tabs, the generic versions of Sanofi-Aventis’ Allegra and Allegra D-12
products. Teva Pharmaceutical Industries Ltd.
TEVA currently has
Rx approval for these products, and Teva and Sanofi-Aventis have settled
their Paragraph IV/Hatch-Waxman litigation.
Allegra 180 mg, 60 mg, and Allegra D-12 are indicated for the relief of
symptoms associated with seasonal allergies. Sanofi-Aventis has applied to
the FDA for the Rx-to-OTC switch of these drugs. Prior to generic
competition entering the Fexofenadine Rx market in 2005, Allegra 180 mg and
60 mg had combined annual sales of approximately $1.5 billion, and in 2009,
Allegra D-12 had annual sales of $600 million according to data provided by
Wolters-Kluwer.
Perrigo’s Chairman and CEO Joseph C. Papa stated, “This is another
example of Perrigo’s strategic focus on making quality healthcare more
affordable to American consumers by introducing new Rx-to-OTC switch
products.”
Perrigo Company is a leading global healthcare supplier that develops,
manufactures and distributes OTC and generic prescription pharmaceuticals,
nutritional products, infant formula, active pharmaceutical ingredients
(API) and consumer products. The Company is the world’s largest
manufacturer of OTC pharmaceutical products for the store brand market. The
Company’s primary markets and locations of manufacturing and logistics
operations are the United States, Australia, Israel, Mexico and the United
Kingdom.
For more information, click on Perrigo.Com
a>>
